HER4 Therapeutic Perspectives
Competing therapies, compared. Emerging science, explained. Understand how treatments work, what the evidence shows and why the differences matter.
A growing research library
Two ways into the science: Therapy Comparisons examines competing and complementary treatments; Science Explained unpacks the technologies changing how we treat disease. Both start with the biology and distinguish demonstrated benefit from a promising hypothesis.
Combined feature · Metabolic disease · October 30, 2026
A deep scientific and clinical comparison of semaglutide, tirzepatide, retatrutide and amylin—with diagrams, receptor mechanisms, and readable benefits versus trade-offs.
Read the combined feature →Therapy comparison · Oncology · October 24, 2026
Moderna’s individualized neoantigen vaccine plus Keytruda versus established adjuvant, neoadjuvant and advanced melanoma approaches. What Phase 3 proves—and does not.
Read the melanoma comparison →Therapy comparison · Hematology · October 17, 2026
Two genetic approaches to sickle cell disease: how they work, what the trials establish and why the treatment journey matters.
Read the sickle cell perspective →This week’s expanded Science Explained and Therapeutic Perspectives analysis appears as one combined feature above.
Science explained · Oncology · October 24, 2026
Tumor sequencing, neoantigen selection, mRNA manufacture and PD-1 blockade—followed by a close look at new Phase 3 data and remaining unknowns.
Explore the personalized vaccine science →Science explained · Oncology · October 17, 2026
Find a molecular target. See where the tracer goes. Deliver a therapeutic payload. How imaging and targeted radiation work together—and what the clinical evidence shows.
Explore the science of theranostics →How we evaluate a therapy
What problem does the therapy address, and why should its mechanism matter?
Who was treated, what was the comparator and which outcomes actually improved?
Where could the approach fit, what limits it and which next result would change the assessment?
Dated archive
Each issue retains its evidence cutoff. Later perspectives can return to an earlier thesis and explain what held up, what failed and what remains unresolved.
Beyond GLP-1: Can triple agonists move the needle?Combined feature · Science Explained & Therapeutic Perspectives · Metabolic diseaseA cancer vaccine made for one person: How Moderna and Keytruda work togetherScience Explained 03 · Neoantigen mRNA vaccines · OncologyMelanoma treatment: Does a personalized cancer vaccine change the standard of care?Therapy Comparisons 03 · Melanoma · OncologyWhat Exactly Is Theranostics — and Why Is It Getting People Excited?Science Explained 02 · Theranostics · OncologySickle cell disease: Restarting fetal hemoglobin. Adding a new defense.Therapy Comparisons 02 · Casgevy & Lyfgenia · HematologyPancreatic cancer: Blocking its growth. Teaching the immune system to find it.Therapy Comparisons 01 · Daraxonrasib & autogene cevumeran · OncologyAntibody–drug conjugates: Why the delivery system matters.Science Explained 01 · ADCs and the Seagen acquisition · OncologyLooking for our market analysis? Read Market Perspectives →
Independent perspective. Institutional discipline. Clear recommendations.